Bioxyne Posts 112% Revenue Growth, Secures $1.6M UK Government Grant
Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.
- Record $17.2 million revenue in Q2 FY2026, up 21% quarter-on-quarter
- Entry into UK, Germany, and LATAM markets with significant growth potential
- Positive operating cash flow of $2.5 million and $7.6 million cash on hand
- Secured $1.6 million Scottish government grant for new UK GMP facility
- FY26 guidance raised to $65–75 million revenue and $11.5–13.5 million EBITDA
Record Quarter Highlights Bioxyne’s Momentum
Bioxyne Limited has announced a standout second quarter for FY2026, reporting $17.2 million in revenue; a 21% increase from the previous quarter and more than doubling compared to the same period last year. This surge reflects the company’s successful expansion into new international markets, including the UK, Germany, and Latin America, alongside robust growth in its psychedelics and branded health product segments.
Cash receipts hit a record $18.4 million, supported by positive operating cash flow of $2.5 million and a strong cash position of $7.6 million at quarter’s end. This financial strength is bolstered by a $1.6 million non-dilutive grant from the Scottish Government, earmarked for Bioxyne’s new Good Manufacturing Practice (GMP) facility in the Scottish Borders, positioning the company to capture demand in the UK’s rapidly growing cannabis market.
Strategic Growth Drivers and Market Expansion
Bioxyne’s growth is driven by expanded Australian manufacturing capacity and a diversified product portfolio that includes white-label medicines, consumer health products under the Dr Watson® brand, and pioneering psychedelics formulations such as GMP-compliant MDMA and psilocybin capsules. The company has secured significant contracts with industry players like Curaleaf and Remidose, the latter involving THC pastilles targeting Central American markets.
The company’s entry into the UK and German markets marks a critical step in its global expansion strategy, supported by a recent dual listing on the Frankfurt Stock Exchange to enhance liquidity and investor access in Europe. These moves align with Bioxyne’s ambition to lead in medical cannabis and psychedelics, sectors forecasted to experience substantial growth over the coming decade.
Outlook and Operational Enhancements
Looking ahead, Bioxyne has set FY2026 revenue guidance between $65 million and $75 million, with EBITDA expected to range from $11.5 million to $13.5 million. The company anticipates maintaining positive cash flow for the full year, underpinned by strategic investments in inventory and operational efficiencies, including the integration of the Oracle NetSuite ERP system commenced in January 2026.
Bioxyne’s recognition as one of Deloitte’s Tech Fast 50 fastest-growing Australian companies underscores its rapid ascent and innovation in pharmaceutical manufacturing. The company’s focus on regulatory compliance, product innovation, and market diversification positions it well to capitalise on the expanding global demand for controlled drugs and novel therapeutics.
Bottom Line?
Bioxyne’s record quarter and strategic expansions set the stage for a transformative year in the evolving pharmaceutical and psychedelics landscape.
Questions in the middle?
- How will Bioxyne manage regulatory challenges in new international markets?
- What is the timeline for scaling production at the new UK GMP facility?
- How will emerging psychedelics revenues impact overall profitability in FY27?
